Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- HPB’s Economic Affairs Division to Set Up Study Group to Monitor Progress of Roadmap to Promote Generic Drug Use
March 12, 2014
- Revisions of Prefectural Disaster Plans for Drug Distribution Almost Complete
March 11, 2014
- PAFSC’s Committee on Blood Programs Approves Standard Prices of Raw Plasma to Rise in FY2014 Due to Hike in Consumption Tax
March 11, 2014
- PMDA Raises Caution on Teratogenicity of Keratosis Treatment Tigason, Urges Use Only in Serious Cases
March 11, 2014
- Kitasato Daiichi Cannot Secure Flu Vaccine Production Capacity for 20 Million People by State Project Deadline
March 10, 2014
- Opposition Lawmaker Throws Doubts on Key Premium Given to Dellegra
March 7, 2014
- MHLW to Issue Notification Asking Doctors to Refrain from Selecting “No Substitution” Checkbox When Writing Prescriptions
March 7, 2014
- Basic Fees Paid to Pharmacies and Hospitals with Low Price Settlement Rates to Be Reduced under the New Rule from January 2015
March 7, 2014
- Pharmacists Will Be Required to Explain Reasons for Not Dispensing Generics in Case of Generic Name Prescriptions from FY2014
March 7, 2014
- MHLW to Set Up Study Group to Discuss Legislation to Regulate Clinical Research “by April at the Latest”
March 6, 2014
- Market Share of Generics Stood at 46.9% Based on New Calculation Method as of September Last Year: MHLW
March 6, 2014
- Januvia/Glactiv to See 10.1% Price Cut Due to Re-Pricing Following Market Expansion
March 6, 2014
- MHLW to Conduct Hearings with Takeda on Blopress Research Data
March 5, 2014
- Pfizer No. 1 Premium Getter in FY2014 Revision, Non-Japanese Makers Sweep Top 10 List
March 5, 2014
- FY2014 NHI Revision Sees Price Cut of 5.64% without Tax Surcharges, 1,118 Long-Listed Products Subject to New Rule
March 5, 2014
- MHLW to Draft Guidelines to Prevent Misuse of Research Funding, Improper Research Activities
March 5, 2014
- Planned Japanese NIH is Research Supporting Agency, Different from Original: Gov't
March 4, 2014
- MHLW Requests University of Tokyo to Investigate SIGN Trial Issues
March 4, 2014
- Drugs Under Ongoing Review for Risk by PMDA Include Mirtazapine for QT Prolongation and Ventricular Tachycardia
March 4, 2014
- PMDA Kansai Branch Poised to Offer More Regulatory Affairs Advice, Inspection Unit to Go Live in April
March 4, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…